Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL, Brouns -JWM, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JSA, De Ruysscher DKM, Van den Heuvel MM, Dingemans AC. Hendriks LEL, et al. Among authors: wijsman r. Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008. Epub 2016 Sep 9. Lung Cancer. 2016. PMID: 27794410 Free article.
External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy.
Dankers FJWM, Wijsman R, Troost EGC, Tissing-Tan CJA, Kwint MH, Belderbos J, de Ruysscher D, Hendriks LE, de Geus-Oei LF, Rodwell L, Dekker A, Monshouwer R, Hoffmann AL, Bussink J. Dankers FJWM, et al. Among authors: wijsman r. Radiother Oncol. 2018 Nov;129(2):249-256. doi: 10.1016/j.radonc.2018.07.021. Epub 2018 Sep 18. Radiother Oncol. 2018. PMID: 30241789
Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands.
Evers J, Hendriks LEL, De Jaeger K, Wijsman R, De Ruysscher D, Terhaard C, van der Sangen M, Siesling S, Struikmans H, Aarts MJ. Evers J, et al. Among authors: wijsman r. Lung Cancer. 2021 Dec;162:61-70. doi: 10.1016/j.lungcan.2021.10.011. Epub 2021 Oct 28. Lung Cancer. 2021. PMID: 34739855 Free article.
Corrigendum to "Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands" [Lung Cancer 162C (2021) 61-70].
Evers J, Hendriks LEL, De Jaeger K, Wijsman R, De Ruysscher D, Terhaard C, van der Sangen M, Siesling S, Struikmans H, Aarts MJ. Evers J, et al. Among authors: wijsman r. Lung Cancer. 2022 May;167:107. doi: 10.1016/j.lungcan.2021.12.012. Epub 2021 Dec 29. Lung Cancer. 2022. PMID: 34973817 No abstract available.
Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.
Kievit H, Muntinghe-Wagenaar MB, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, Slingers G, de Vries R, Groen HJM, Kerstjens HAM, van der Wekken AJ, Hiltermann TJN. Kievit H, et al. Among authors: wijsman r. Lung Cancer. 2023 Apr;178:96-102. doi: 10.1016/j.lungcan.2023.02.004. Epub 2023 Feb 7. Lung Cancer. 2023. PMID: 36806899 Free article. Clinical Trial.
External validation of NTCP-models for radiation pneumonitis in lung cancer patients treated with chemoradiotherapy.
Niezink AGH, van der Schaaf A, Wijsman R, Chouvalova O, van der Wekken AJ, Rutgers SR, Pieterman RM, van Putten JWG, de Hosson SM, van der Leest AHD, Ubbels JF, Woltman-van Iersel M, Widder J, Langendijk JA, Muijs CT. Niezink AGH, et al. Among authors: wijsman r. Radiother Oncol. 2023 Sep;186:109735. doi: 10.1016/j.radonc.2023.109735. Epub 2023 Jun 14. Radiother Oncol. 2023. PMID: 37327975 Free article.
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.
Cortiula F, Hendriks LEL, Wijsman R, Houben R, Steens M, Debakker S, Canters R, Trovò M, Sijtsema NM, Niezink AGH, Unipan M, Urban S, Michelotti A, Dursun S, Bootsma G, Hattu D, Nuyttens JJ, Moretti E, Taasti VT, De Ruysscher D. Cortiula F, et al. Among authors: wijsman r. Radiother Oncol. 2024 Jan;190:110019. doi: 10.1016/j.radonc.2023.110019. Epub 2023 Nov 22. Radiother Oncol. 2024. PMID: 38000689 Free article.
Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.
Kievit H, Muntinghe-Wagenaar MB, Abdulahad WH, Rutgers A, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, van der Leij MJ, Bijzet J, Groen HJM, Kerstjens HAM, van der Wekken AJ, Kroesen BJ, Hiltermann TJN. Kievit H, et al. Among authors: wijsman r. Cancers (Basel). 2024 Jul 19;16(14):2592. doi: 10.3390/cancers16142592. Cancers (Basel). 2024. PMID: 39061230 Free PMC article.
44 results